Anticoagulation for Patients With Concomitant Atrial Fibrillation and End-Stage Renal Disease: A Systematic Review and Network Meta-Analysis.
Ting-Wei KaoZheng-Wei ChenYen-Hung LinPublished in: Journal of the American Heart Association (2024)
For dialysis-dependent populations, dabigatran and rivaroxaban were associated with better efficacy, while dabigatran and apixaban demonstrated better safety. No anticoagulation was a noninferior alterative, and VKAs were associated with the worst outcomes.
Keyphrases
- atrial fibrillation
- end stage renal disease
- chronic kidney disease
- peritoneal dialysis
- oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- direct oral anticoagulants
- heart failure
- percutaneous coronary intervention
- venous thromboembolism
- acute coronary syndrome
- type diabetes
- genetic diversity
- coronary artery disease
- left ventricular